Treasurer of the State of North Carolina Decreases Position in Bristol-Myers Squibb (NYSE:BMY)

Treasurer of the State of North Carolina lowered its stake in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 1.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 1,050,308 shares of the biopharmaceutical company's stock after selling 15,910 shares during the period. Treasurer of the State of North Carolina owned approximately 0.05% of Bristol-Myers Squibb worth $59,405,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the stock. Fairway Wealth LLC purchased a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at about $28,000. Comprehensive Financial Planning Inc. PA purchased a new position in shares of Bristol-Myers Squibb in the 4th quarter worth approximately $34,000. Westend Capital Management LLC bought a new position in shares of Bristol-Myers Squibb in the fourth quarter valued at approximately $38,000. Tacita Capital Inc bought a new stake in Bristol-Myers Squibb during the fourth quarter worth $39,000. Finally, M Holdings Securities Inc. purchased a new position in Bristol-Myers Squibb in the fourth quarter worth $39,000. Institutional investors own 76.41% of the company's stock.

Insider Transactions at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat bought 1,823 shares of the firm's stock in a transaction on Friday, February 14th. The stock was acquired at an average price of $54.84 per share, with a total value of $99,973.32. Following the completion of the purchase, the executive vice president now owns 63,932 shares of the company's stock, valued at approximately $3,506,030.88. This trade represents a 2.94 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.09% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on BMY shares. Jefferies Financial Group upgraded Bristol-Myers Squibb from a "hold" rating to a "buy" rating and lifted their target price for the stock from $63.00 to $70.00 in a research note on Monday, December 16th. The Goldman Sachs Group reissued a "neutral" rating and set a $55.00 target price (down from $67.00) on shares of Bristol-Myers Squibb in a research report on Tuesday, April 8th. Cantor Fitzgerald raised their target price on Bristol-Myers Squibb from $50.00 to $55.00 and gave the stock a "neutral" rating in a research report on Tuesday, February 4th. Wells Fargo & Company boosted their price target on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an "equal weight" rating in a research report on Friday, February 7th. Finally, Citigroup raised their price target on Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a "neutral" rating in a report on Tuesday, January 28th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $57.67.

Bristol-Myers Squibb Trading Down 3.1 %

NYSE:BMY traded down $1.61 during trading hours on Tuesday, reaching $49.73. The company's stock had a trading volume of 7,239,162 shares, compared to its average volume of 12,911,075. The firm has a 50-day simple moving average of $57.54 and a 200-day simple moving average of $56.78. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $63.33. The firm has a market capitalization of $101.19 billion, a price-to-earnings ratio of -11.25, a PEG ratio of 2.07 and a beta of 0.41. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share for the quarter, topping analysts' consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. Research analysts expect that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Friday, April 4th will be given a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a dividend yield of 4.99%. The ex-dividend date is Friday, April 4th. Bristol-Myers Squibb's dividend payout ratio is currently -56.11%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.